5 completed. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
Follow talabostat: new trials by email Literature Review of talabostat trials Research Report on talabostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype Talabostat, Pembrolizumab - Prostate Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 97 | 2019-06-10 | 2026-11-10 |
| Study of Talabostat and Cisplatin in Advanced Melanoma talabostat (PT-100) tablets, cisplatin - Melanoma, Skin Cancer | Phase 2 | Completed | Point Therapeutics | 2007-06-08 | ||
| Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) Talabostat mesylate (PT-100) tablets, Rituximab - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Point Therapeutics | 2015-03-25 | ||
| Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer talabostat (PT-100) tablets, Docetaxel - Lung Cancer | Phase 2 | Completed | Point Therapeutics | 2007-06-08 | ||
| Study of Talabostat in Advanced Melanoma talabostat (PT-100) tablets - Melanoma, Skin Cancer | Phase 2 | Completed | Point Therapeutics | 2007-06-08 |
Melanoma (2) · Skin Neoplasms (2) · Carcinoma, Small Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Neuroendocrine Tumors (1) · Prostatic Neoplasms (1)
Point Therapeutics (4) · BioXcel Therapeutics Inc (1)
United States (5) · United Kingdom (1)